Presented updated Phase 1/2 data at
Reached alignment with the
Initiated a dose-ranging clinical study of zolucatetide in familial adenomatous polyposis (FAP)
Entered into a clinical collaboration with Revolution Medicines to evaluate zolucatetide in combination with zoldonrasib and cetuximab in patients with previously treated RAS G12D mutant microsatellite stable metastatic colorectal cancer (MSS CRC)
Ended the third quarter with
“With each successive clinical update, we are building a stronger foundation for zolucatetide as a unique medicine with the potential to make a meaningful difference for patients across multiple diseases,” said
Recent Business Highlights and Anticipated Milestones
Continued Advancement of Zolucatetide
Desmoid tumors
- Presented compelling clinical data from a
June 22, 2026 , data cut of the ongoing Phase 1/2 trial of zolucatetide at theEuropean Society for Medical Oncology (ESMO) Congress 2026, demonstrating:- An objective response rate (ORR) of 72.2% (13/18) among patients evaluable at the 32-week landmark who received a starting dose of =450 mg
- A disease control rate (DCR) of 100%, with no disease progression, across all 46 response-evaluable patients receiving a starting dose of =450 mg
- A favorable safety and tolerability profile now shown in 76 patients, with no treatment discontinuations due to treatment-related adverse events (TRAEs)
- Reached alignment with the
U.S. Food and Drug Administration (FDA) on a global Phase 3 trial design; plan to initiate the randomized, double-blind PEDESTAL Phase 3 registrational trial in the first half of 2027 with topline results anticipated in 2029 - Selected for an oral presentation at the
Connective Tissue Oncology Society (CTOS) Annual Meeting inNovember 2026 , featuring data from theJune 22, 2026 , data cut - Initiated a Phase 1/2 clinical trial of zolucatetide in patients with desmoid tumors in
China to support the planned inclusion of patients inChina in the global PEDESTAL Phase 3 registrational trial
Familial adenomatous polyposis
- Initiated a dose-ranging clinical cohort as part of the ongoing Phase 1/2 trial to evaluate zolucatetide in patients with FAP and identify the optimal dose and regimen
- Anticipate disclosing translational data demonstrating on-target activity at a medical meeting in the first quarter of 2027
- Anticipate disclosing clinical data from additional patients with FAP in the first quarter of 2027, building on compelling early observations of duodenal polyp reductions in two patients
Adamantinomatous craniopharyngioma
- Anticipate disclosing updated clinical data from additional patients with ACP in the first half of 2027, building on encouraging early antitumor activity in three patients
Hepatocellular carcinoma and additional Wnt/ß-catenin-driven tumors
- Anticipate disclosing additional clinical data in HCC at a medical meeting in the first quarter of 2027, building on evidence of early activity in a heavily pretreated patient
- Continue evaluating zolucatetide across additional Wnt/ß-catenin-driven tumor types as part of the ongoing Phase 1/2 clinical trial
Clinical collaboration with Revolution Medicines in RAS G12D mutant MSS CRC
- Entered into a clinical collaboration with Revolution Medicines (RevMed) to evaluate zolucatetide in combination with RevMed’s zoldonrasib, an investigational, oral RAS(ON) G12D-selective covalent tri-complex inhibitor, and cetuximab, an EGFR inhibitor, in patients with previously treated RAS G12D mutant MSS CRC; Parabilis will sponsor and conduct the study, with RevMed supplying zoldonrasib and equally sharing the costs of the trial
- Supported by clinical translational data from the Phase 1/2 trial showing reciprocal upregulation of mitogen-activated protein kinase (MAPK) and downregulation of the Wnt pathway in patients with MSS CRC treated with zolucatetide, alongside a manageable safety and tolerability profile
- Also supported by preclinical data showing enhanced tumor growth inhibition when zolucatetide was combined with zoldonrasib in a CRC patient-derived xenograft model
Advancement of the Helicon Platform and Discovery Pipeline
- Continued advancing wholly owned preclinical programs, including ERG and allosteric ARON degraders in prostate cancer and a ß-catenin degrader program, alongside ongoing research under the strategic collaboration with Regeneron to develop Antibody-Helicon Conjugates (AHCs) targeting intracellular proteins
Corporate Updates
- Appointed
Craig L. Tendler , M.D., to the Board of Directors inAugust 2026 , bringing extensive oncology drug development and regulatory experience
Upcoming Investor Conferences
- Announced that
Mathai Mammen , M.D., Ph.D., Chairman, CEO and President, will deliver a company presentation at theJefferies Global Healthcare Conference inLondon, UK , onMonday, November 16, 2026 , at12:30 p.m. GMT /7:30 a.m. EST , and participate in a fireside chat at theEvercore ISI 9th Annual Healthcare Conference onMonday, November 30, 2026 , at3:50 p.m. EST ; webcasts will be available at https://investors.parabilismed.com/
Third Quarter 2026 Financial Results
Cash position and runway: Cash, cash equivalents and marketable securities were
Revenue: Revenues for the quarter ended
R&D expenses: Research and development expenses were
G&A expenses: General and administrative expenses were
Net loss: Net loss was
About Parabilis Medicines
Parabilis Medicines (Nasdaq: PBLS) is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking biologically important targets long considered undruggable. The Company has pioneered a new class of alpha-helical peptides – Helicons™ – capable of modulating intracellular proteins that have historically been beyond the reach of conventional medicines. The Company's lead investigational medicine, zolucatetide, is the first and only direct inhibitor of the ß-catenin:TCF interaction, a central node in the Wnt/ß-catenin pathway that has eluded drug developers for decades. Zolucatetide is being evaluated in the clinic across multiple Wnt/ß-catenin-driven diseases, including desmoid tumors, familial adenomatous polyposis (FAP), adamantinomatous craniopharyngioma (ACP), hepatocellular carcinoma (HCC) and a range of other rare and common solid tumor indications. Beyond zolucatetide, Parabilis is pursuing a follow-on ß-catenin degrader program and advancing additional Helicon-based programs focused on other challenging targets, including ERG and allosteric ARON in prostate cancer, where we believe our medicines could have life-altering impact. For more information, visit www.parabilismed.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: the clinical development of zolucatetide for the treatment of desmoid tumors, FAP, ACP, HCC, CRC and other rare, Wnt-driven tumors, including the initiation, timing, progress, results and future data releases of our ongoing and planned clinical trials; the expected initiation and timing of the Company’s planned Phase 3 registrational trial in desmoid tumors; the expected timing and results of the ongoing Phase 1/2 study in desmoid tumors; the expected enrollment and timing of certain clinical studies and patient cohorts in FAP, CRC and other Wnt-driven tumors; the expected timing and results of the Company’s preclinical development of its ERG degrader, ARON degrader and ß-catenin degrader development candidates; the potential of the Company’s Helicon™ technology platform; expectations regarding the development of any future product candidates using the Company’s Helicon™ technology platform; expectations regarding the efficacy, tolerability and commercial potential of zolucatetide; and expectations for the Company’s uses of capital, expenses and financial results, including its cash runway into 2030.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks and uncertainties that could negatively affect the Company’s business, operating results, financial condition and stock value. Factors that could cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release include, without limitation: risks relating to the Company’s research and development activities; the Company’s ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; the Company’s ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining the Company’s intellectual property protections; and risks related to the competitive landscape for the Company’s product candidates; as well as other risks and uncertainties described in greater detail in “Risk Factors,” in the Company’s most recent Quarterly Report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent the Company’s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Contacts
Media Contact
Jessica Freifeld
media@parabilismed.com
Investor Contact
Tom Kotarakos
investors@parabilismed.com
| | ||||||||
| Condensed Consolidated Balance Sheets (in thousands) (unaudited) | ||||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 521,198 | $ | 27,711 | ||||
| Accounts receivable - related party | 443 | — | ||||||
| Marketable securities | 350,425 | — | ||||||
| Prepaid expenses and other current assets | 6,953 | 1,647 | ||||||
| Total current assets | 879,019 | 29,358 | ||||||
| Property and equipment, net | 9,506 | 6,715 | ||||||
| Restricted cash | 2,855 | 2,855 | ||||||
| Operating lease right-of-use assets | 34,291 | 39,360 | ||||||
| Marketable securities, non-current | 201,309 | — | ||||||
| Other assets | 4,262 | 2,532 | ||||||
| Total assets | $ | 1,131,242 | $ | 80,820 | ||||
| Liabilities, convertible preferred stock and stockholders’ equity (deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 20,209 | $ | 17,272 | ||||
| Accrued expenses and other current liabilities | 24,012 | 18,630 | ||||||
| Operating lease liabilities, current portion | 7,810 | 7,174 | ||||||
| Deferred revenue, current portion | 13,544 | — | ||||||
| Finance lease liabilities, current portion | 684 | 638 | ||||||
| Term loan, net of discount | 2,000 | 13,077 | ||||||
| Total current liabilities | 68,259 | 56,791 | ||||||
| Operating lease liabilities, net of current portion | 30,381 | 36,341 | ||||||
| Finance lease liabilities, net of current portion | 951 | 1,470 | ||||||
| Deferred revenue, net of current portion | 27,304 | — | ||||||
| Other liabilities | — | 2,742 | ||||||
| Total liabilities | 126,895 | 97,344 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock | — | 509,971 | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Preferred stock | — | — | ||||||
| Common stock | 12 | — | ||||||
| Non-voting common stock | — | — | ||||||
| Additional paid-in capital | 1,690,022 | 15,009 | ||||||
| Accumulated other comprehensive loss | (1,913 | ) | — | |||||
| Accumulated deficit | (683,774 | ) | (541,504 | ) | ||||
| Total stockholders’ equity (deficit) | 1,004,347 | (526,495 | ) | |||||
| Total liabilities, convertible preferred stock and stockholders’ equity (deficit) | $ | 1,131,242 | $ | 80,820 | ||||
Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Collaboration revenue | $ | 671 | $ | — | $ | 819 | $ | — | ||||||||
| Collaboration revenue - related party | 1,443 | — | 1,443 | — | ||||||||||||
| Total revenue | 2,114 | — | 2,262 | — | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 45,597 | 28,199 | 122,727 | 92,230 | ||||||||||||
| General and administrative | 11,253 | 6,646 | 32,610 | 19,376 | ||||||||||||
| Total operating expenses | 56,850 | 34,845 | 155,337 | 111,606 | ||||||||||||
| Loss from operations | (54,736 | ) | (34,845 | ) | (153,075 | ) | (111,606 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Interest income | 10,369 | 711 | 16,987 | 3,017 | ||||||||||||
| Interest expense | (124 | ) | (398 | ) | (626 | ) | (1,193 | ) | ||||||||
| Sublease income - related party | — | 1,057 | — | 3,171 | ||||||||||||
| Change in fair value of simple agreement for future equity | — | — | (5,556 | ) | — | |||||||||||
| Total other income, net | 10,245 | 1,370 | 10,805 | 4,995 | ||||||||||||
| Net loss | $ | (44,491 | ) | $ | (33,475 | ) | $ | (142,270 | ) | $ | (106,611 | ) | ||||
| Cumulative dividends on convertible preferred stock | — | (10,395 | ) | (32,181 | ) | (30,360 | ) | |||||||||
| Deemed dividend upon down-round of convertible preferred stock | — | — | (7,875 | ) | — | |||||||||||
| Net loss allocable to common stockholders | $ | (44,491 | ) | $ | (43,870 | ) | $ | (182,326 | ) | $ | (136,971 | ) | ||||
| Net loss per share allocable to common stockholders, basic and diluted | $ | (0.36 | ) | $ | (21.66 | ) | $ | (3.51 | ) | $ | (67.78 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 123,593,149 | 2,025,284 | 51,962,288 | 2,020,689 | ||||||||||||
| Comprehensive loss: | ||||||||||||||||
| Net loss | $ | (44,491 | ) | $ | (33,475 | ) | $ | (142,270 | ) | $ | (106,611 | ) | ||||
| Unrealized gains (losses) on marketable securities | (1,895 | ) | — | (1,913 | ) | (21 | ) | |||||||||
| Comprehensive loss | $ | (46,386 | ) | $ | (33,475 | ) | $ | (144,183 | ) | $ | (106,632 | ) | ||||
Source: 